Pfizer's Sigvotatug Vedotin Misses Overall Survival Goal in Phase 3 Lung Cancer Trial, Salvaging a Signal in Second-Line Patients
Pfizer's integrin beta-6 ADC failed to beat docetaxel on overall survival across the full SigVie-002 population, but showed a stronger trend in the two-thirds of patients with one prior line of therapy.